Cardioplegia Strategies in Aortic Stenosis: A Focused Review of Current Evidence for Surgical Considerations
- 1Department of Cardiac Surgery, St Thomas’ Hospital, SE1 7EH London, UK
- 2Department of Physiology, Anatomy, and Genetics, University of Oxford, OX1 3PT Oxford, UK
Abstract
Severe aortic stenosis (AS) exposes the hypertrophied myocardium to cardioplegic arrest in the setting of increased left ventricle (LV) mass, interstitial fibrosis, impaired relaxation, coronary microvascular dysfunction, and reduced perfusion reserve. These abnormalities may increase susceptibility to ischemic injury and complicate homogeneous cardioplegic delivery. This focused narrative review synthesizes physiological and clinical evidence on cardioplegia composition, temperature, delivery route, dosing, redosing, and myocardial protection during prolonged aortic cross-clamping in adults undergoing surgical aortic valve replacement. AS-specific comparative studies remain limited, generally small, and frequently reliant on biochemical markers; meanwhile, larger observational cohorts and contemporary randomized aortic valve replacement (AVR) trials also vary substantially in patient selection and myocardial protection protocols. Although some studies have associated cold blood cardioplegia with lower biomarker release than cold crystalloid cardioplegia, and cold maintenance strategies with less biochemical injury than warm cardioplegia, no formulation, temperature, or delivery route has demonstrated consistent superiority in clinically important outcomes. Limited historical evidence also suggests that body weight-based dosing may inadequately reflect myocardial requirements in marked LV hypertrophy, but no validated LV mass-based regimen currently exists. Therefore, cardioplegia in severe AS should be considered within a comprehensive myocardial protection protocol incorporating composition, temperature, dose, delivery route, redosing strategy, myocardial phenotype, associated valve or coronary disease, and anticipated cross-clamp duration. Prospective AS-specific studies using standardized protocols, LV mass stratification, and clinically meaningful outcomes are required.
Related
- Surgical Timing Considerations in osteosarcoma patients with autism spectrum disorder: A systematic review of indirect evidence and a conceptual framework
- Surgical explantation following early transcatheter aortic valve failure: Technical considerations for complex situations.
- Evidence landscape for surgical site infection prevention strategies in low- and middle-income countries: a scoping review of literature for intervention development as part of the IMPRESS study
- Complex Cardiac Tumor with Concomitant Pericardial Effusion and Hemodynamic Compromise in a Septuagenarian: Case Report of Anesthetic and Surgical Considerations
- Early Nrf2/HO-1 signaling activation following surgical decompression in a rat model of lumbar spinal stenosis-induced neurogenic intermittent claudication
BibTeX
@article{ho2026cardioplegia,
title = {{Cardioplegia Strategies in Aortic Stenosis: A Focused Review of Current Evidence for Surgical Considerations}},
author = {Minji Ho and Benjamin Chapman and Gianluca Lucchese and Paolo Bosco},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm52775},
url = {https://doi.org/10.31083/rcm52775},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cardioplegia Strategies in Aortic Stenosis: A Focused Review of Current Evidence for Surgical Considerations
AU - Minji Ho
AU - Benjamin Chapman
AU - Gianluca Lucchese
AU - Paolo Bosco
PY - 2026
DA - 2026/10/14
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm52775
UR - https://doi.org/10.31083/rcm52775
AB - Severe aortic stenosis (AS) exposes the hypertrophied myocardium to cardioplegic arrest in the setting of increased left ventricle (LV) mass, interstitial fibrosis, impaired relaxation, coronary microvascular dysfunction, and reduced perfusion reserve. These abnormalities may increase susceptibility to ischemic injury and complicate homogeneous cardioplegic delivery. This focused narrative review synthesizes physiological and clinical evidence on cardioplegia composition, temperature, delivery route, dosing, redosing, and myocardial protection during prolonged aortic cross-clamping in adults undergoing surgical aortic valve replacement. AS-specific comparative studies remain limited, generally small, and frequently reliant on biochemical markers; meanwhile, larger observational cohorts and contemporary randomized aortic valve replacement (AVR) trials also vary substantially in patient selection and myocardial protection protocols. Although some studies have associated cold blood cardioplegia with lower biomarker release than cold crystalloid cardioplegia, and cold maintenance strategies with less biochemical injury than warm cardioplegia, no formulation, temperature, or delivery route has demonstrated consistent superiority in clinically important outcomes. Limited historical evidence also suggests that body weight-based dosing may inadequately reflect myocardial requirements in marked LV hypertrophy, but no validated LV mass-based regimen currently exists. Therefore, cardioplegia in severe AS should be considered within a comprehensive myocardial protection protocol incorporating composition, temperature, dose, delivery route, redosing strategy, myocardial phenotype, associated valve or coronary disease, and anticipated cross-clamp duration. Prospective AS-specific studies using standardized protocols, LV mass stratification, and clinically meaningful outcomes are required.
SN - 1530-6550
SN - 2153-8174
ER -